Elsevier

Vaccine

Volume 31, Issue 46, 4 November 2013, Pages 5422-5429
Vaccine

Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies

https://doi.org/10.1016/j.vaccine.2013.09.003Get rights and content

Highlights

  • Chimeric BPV VLP vaccines were constructed to present HIV-1 MPER epitopes.

  • The induction of systemic and mucosal antibody responses was assessed in mice.

  • The induced IgG and sIgA recognized the MPER epitopes presented by HIV-1.

  • IgG and sIgA induced by L1-MPER are able to neutralize clade B and clade C HIV-1.

Abstract

Two conserved epitopes, located in the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 (HIV-1) gp41, are recognized by two HIV-1 broadly neutralizing antibodies 2F5 and 4E10, and are promising targets for vaccine design in efforts to elicit anti-HIV-1 broadly neutralizing antibodies. Since most HIV-1 infections initiate at mucosal surfaces, induction of mucosal neutralizing antibodies is necessary and of utmost importance to counteract HIV-1 infection. Here, we utilized a mucosal vaccine vector, bovine papillomavirus (BPV) virus-like particles (VLPs), as a platform to present HIV-1 neutralizing epitopes by inserting the extended 2F5 or 4E10 epitope or the MPER domain into D-E loop of BPV L1 respectively. The chimeric VLPs presenting MPER domain resembled the HIV-1 natural epitopes better than the chimeric VLPs presenting single epitopes. Oral immunization of mice with the chimeric VLPs displaying the 2F5 epitope or MPER domain elicited epitope-specific serum IgGs and mucosal secretory IgAs. The induced antibodies specifically recognized the native conformation of MPER in the context of HIV-1 envelope protein. The antibodies induced by chimeric VLPs presenting MPER domain are able to partially neutralize HIV-1 viruses from clade B and clade C.

Introduction

Although anti-HIV-1 (human immunodeficiency virus type 1) drugs are effective in controlling development of AIDS, HIV-1 infection still remains an enormous problem worldwide. An effective HIV-1 vaccine is urgently needed but its development is hindered by the huge variability of the virus. A recent HIV-1 vaccine phase III clinical trial, the RV144 trial conducted in Thailand, for the first time showed modest efficacy against acquisition of infection, which raises hope for developing an effective HIV-1 vaccine [1], [2].

A number of groups have isolated several monoclonal antibodies (mAbs) that can neutralize a variety of HIV-1 isolates [3], [4], [5], [6], [7], [8], [9], [10], [11], [12]. Among those mAbs, 2F5, 4E10, Z13 and the recently reported 10E8 are shown to target conserved epitopes within the membrane-proximal external region (MPER) of gp41 [12], [13], [14], [15], [16], [17], [18], [19], [20], [21]; The isolation of these and other broadly neutralizing antibodies (b12, 2G12, VRC01, CH01 to CH04, PG9, PG16) is a milestone in the field. The epitopes located at the MPER of gp41 recognized by broadly neutralizing mAbs 2F5 and 4E10 are promising targets for vaccine design. Unfortunately, many attempts at eliciting broadly neutralizing antibodies by targeting neutralizing epitopes of MPER failed [22], [23], [24], [25], [26], [27]. Two recent studies reported that presenting the ELDKWA epitope by human rhinovirus [28] or a whole MPER domain with mutations (T569A and I675V) by NCM antigen [29] successfully induced anti-HIV-1 cross-clade neutralizing antibodies.

HIV-1 is transmitted both venereally and hematogeneously and vaginal and rectal mucosa serve as major sites for viral entry and initial infection [30], [31]. Thus, an effective HIV-1 vaccine must elicit both mucosal immunity to prevent entry of HIV-1 into the mucosa, and systemic immunity to restrict viral transmission via blood stream [32]. Bovine papillomavirus 1 (BPV) virus-like particle (VLP) is an ideal mucosal delivery vector that not only carries peptide/protein/DNA to protect them from degradation by the gastric and intestinal environment but also serves as a strong immune activating adjuvant eliciting both mucosal and systemic immune responses via the oral immunization route [27], [33], [34], [35], [36], [37]. Additionally, since BPV is not a natural pathogen for humans, the likelihood of preexisting “vector neutralization” that would presumably attenuate vaccine efficacy is minimized.

In this study, we used BPV VLPs to present HIV-1 gp41 MPER or extended 2F5 epitope and determined if the epitopes are presented in their proper conformation. Induction of systemic and mucosal antibody responses was measured after oral immunization of the chimerical VLPs in mice. We used HIV-1 infected cells and an in vitro neutralization test to assess the binding and neutralizing activities of the induced HIV-1-specific antibodies.

Section snippets

Cell lines

Sf9 (Spodoptera frugiperda) cells were obtained from the American Type Culture Collection and grown at 28 °C in HyGro Sf-PFM insect medium (JR Scientific, Woodland, CA). Human T-lymphoblastic cell lines H9 and CEM-NKR-CCR5 were obtained from the AIDS Research and Reference Reagent Program, NIH [38], [39]. T cells were cultured in L-glutamine containing DMEM medium supplemented with 10% fetal bovine serum, 100 U of penicillin and 100 μg of streptomycin per ml (HyClone, Logan, UT).

Construction and generation of CVLPs

The C-terminal

Design and generation of CVLPs

We used BPV1 L1 VLPs to present HIV gp41 neutralizing epitopes to develop an HIV-1 vaccine. We used an extended 13aa 2F5 epitope, 13aa 4E10 epitope or an MPER peptide containing both epitopes in the vaccine constructs. Three chimeric L1 VLPs were made: 2-1 (presenting ELLELDKWASLWN), 4-1 (presenting NWFDITNWLWYIK) and L1-MPER (presenting ELLELDKWASLWNWFDITNWLWYIK) (Fig. 1A). Purified CVLPs were identified by western-blotting using anti-L1 mAb AU5 (Fig. 1B). Western-blot using 2F5 or 4E10 mAb

Discussion

In this study, we developed chimeric BPV1-gp41 to elicit mucosal and systemic anti-HIV-1 broadly neutralizing antibodies. We inserted the extended 2F5 and 4E10 epitopes as well as MPER domain containing three neutralizing epitopes, into the D-E loop of BPV L1 to broaden the presentation of the HIV-1 2F5/Z13/4E10 epitope on the BPV CVLPs as well as the protection against HIV-1. Our results demonstrated that the MPER-displaying CVLPs induced HIV-specific mucosal and systemic cross-clade

Acknowledgments

The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp41 mAbs 2F5 and 4E10 from Dr. Hermann Katinger; H9 cells, HIV-1MN and HIV-1Bal from Dr. Robert Gallo; HIV-1SE364, UG273, UG274, US4 from Dr. Nelson Michael. This work was supported by a grant from the National Institutes of Health (NIH) (grant # DE019075 to L.Q.).

Conflict of interest: The authors have declared that no financial conflict of interest exists.

References (54)

  • J. Paintsil et al.

    Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation

    Virology

    (1996)
  • C. Pastori et al.

    Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41

    Virology

    (2012)
  • D. Tudor et al.

    HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis

    Mucosal Immunol

    (2009)
  • V. Revaz et al.

    Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants

    Antiviral Res

    (2007)
  • H.J. Cho et al.

    Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants

    Vaccine

    (2010)
  • J.D. Fuchs et al.

    Lessons drawn from recent HIV vaccine efficacy trials

    J Acquir Immune Defic Syndr

    (2010)
  • S. Rerks-Ngarm et al.

    Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

    N Engl J Med

    (2009)
  • D.R. Burton et al.

    Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

    Science

    (1994)
  • J.A. Kessler et al.

    Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates

    AIDS Res Hum Retroviruses

    (1997)
  • Y. Li et al.

    Broad HIV-1 neutralization mediated by CD4-binding site antibodies

    Nat Med

    (2007)
  • A.K. Pilgrim et al.

    Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

    J Infect Dis

    (1997)
  • X. Wu et al.

    Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

    Science

    (2010)
  • L.M. Walker et al.

    Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

    Science

    (2009)
  • J.F. Scheid et al.

    Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding

    Science

    (2011)
  • M. Bonsignori et al.

    Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

    J Virol

    (2011)
  • X. Wu et al.

    Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing

    Science

    (2011)
  • J. Huang et al.

    Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

    Nature

    (2012)
  • Cited by (31)

    • HIV-1 Membrane-Proximal External Region Fused to Diphtheria Toxin Domain-A Elicits 4E10-Like Antibodies in Mice

      2019, Immunology Letters
      Citation Excerpt :

      It may also explain the lower neutralizing activity of 18C8-2 than that of 4E10. In summary, numerous studies have used MPER transplantation onto surface loops of various protein scaffolds to elicit bNAbs [23,24,51–54]. In each case, the MPER fusion proteins induced antibodies that could bind to the MPER epitopes, with several also eliciting weak neutralizing activities.

    • Current and new approaches for mucosal vaccine delivery

      2019, Mucosal Vaccines: Innovation for Preventing Infectious Diseases
    • Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region

      2017, Vaccine
      Citation Excerpt :

      The broadly neutralizing antibodies, 2F5, 4E10 and 10E8, have all also displayed varying levels of reactivity towards lipids, which may further impede the elicitation of these types of antibodies by vaccination [19,20]. Numerous animal studies have failed to elicit robust neutralizing antibody responses using MPER peptides or fusion proteins that are soluble or presented in the context of a lipid membrane [21–28]. This may suggest that the MPER must be presented in the context of gp41 to be able to induce neutralizing antibodies.

    • The case for plant-made veterinary immunotherapeutics

      2016, Biotechnology Advances
      Citation Excerpt :

      VLP-based veterinary vaccines are also being developed to battle among others avian flu, bluetongue disease, PRRSV, and Newcastle disease (McGinnes et al., 2010; Shen et al., 2013; Thuenemann et al., 2013; Uribe-Campero et al., 2015). The VLP platform has some additional advantages as it offers the opportunity to fuse heterologous genes to the viral coat subunits resulting in highly immunogenic chimeric VLPs (Kim et al., 2013; Shen et al., 2013; Zhai et al., 2013). Even though these studies did not target oral delivery of VLPs, they demonstrate that immunogenicity of vaccine antigens could be increased via multimerization of the subunits, an outcome that appears to be especially true for oral immunogens.

    • Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-subtypes

      2016, Journal of Virological Methods
      Citation Excerpt :

      The 56 virus isolates (Table 1) belong to the International Panel of HIV-1 Isolates (Brown et al., 2005) representing the six major globally prevalent strains A, B, C, D, CRF01_AE and CRF02_AG. Available through the NIH AIDS Reagent Program (Cat #11412), they constitute a resource for standardization for studies using different HIV-1 subtypes and are wildly used (Jones et al., 2012; Rosa Borges et al., 2010; Stoddart et al., 2015; Zhai et al., 2013). To ensure consistency of our measurement over time, a 500 μl or 1 ml vial of virus stock was thawed, divided into 100 μl aliquots and stored at −80 °C.

    View all citing articles on Scopus
    View full text